J&J misses quarterly revenue forecasts as Covid sales disappoint
Company maintains full-year revenue outlook even though it will need to more than triple volumes in the fourth quarter
Johnson & Johnson on Tuesday reported lower-than-expected quarterly revenue with sales of its Covid-19 vaccine lower than Wall Street estimates after a string of production setbacks.
The New Brunswick, New Jersey-based company reporting $766m in sales of the shot in the first nine months of 2021 and maintained its 2021 revenue goal of $2.5bn from the vaccine — meaning that sales will have to more than triple in the fourth quarter to meet its forecast.
“We’re still very much committed to the $2.5bn of revenue and the supply that is correlated to that,” CFO Joseph Wolk told investors on a conference call.
The drugmaker earlier this year experienced quality problems at a Baltimore facility that produces the single-dose vaccine, resulting in the wastage of millions of doses.
The J&J shot, once touted an as important tool for vaccinating hard-to-reach areas, is behind its schedule for deliveries in the US and Europe.
The vaccine has the lowest uptake in the US at a time when rivals Moderna and Pfizer are signing up supply deals for booster doses in 2022 and beyond.
“It’s hard to say whether J&J will meet that target, but with the booster guidance coming out soon, that could provide a push to the fourth quarter,” Edwards Jones analyst Ashtyn Evans told Reuters.
The US Food and Drug Administration (FDA) has yet to authorise a booster dose of the J&J vaccine, with a decision expected in days.
J&J’s shares rose almost 2% in morning trade, reversing a pre-market fall, as the company raised its overall adjusted profit forecast and beat earnings estimates.
Sales in its medical devices unit rose 8% to $6.64bn but missed analyst estimates of $6.87bn, hurt by a resurgence in Covid-19 cases due to the Delta variant.
Excluding items, J&J earned $2.60 per share, beating expectations of $2.35 per share, according to Refinitv data.
J&J lifted its 2021 forecast for adjusted earnings per share to between $9.77 and $9.82, from its prior estimates of $9.60 to $9.70.
Overall sales of $23.34bn missed expectations of $23.72bn. Covid-19 vaccine sales of $502m missed estimates of $815m, according to FactSet.
Would you like to comment on this article or view other readers' comments?
Register (it’s quick and free) or sign in now.
Please read our Comment Policy before commenting.